Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

440
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
440
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K
Pharmacovigilance01:19

Pharmacovigilance

1.3K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

977
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
977
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

66
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
66
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

406
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
406

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions.

Atherosclerosis plus·2026
Same author

[Therapeutic inertia: physician, patient, and system-related factors and possible intervention strategies].

Giornale italiano di cardiologia (2006)·2026
Same author

From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: A Monte Carlo simulation within the ITACARE-P registry.

Journal of clinical lipidology·2025
Same author

Clinical and Hemodynamic Implications of Mitral Annular Calcification.

Journal of the Heart Valve Society·2025
Same author

Is cardiac auscultation still needed in a digital world?

Heart (British Cardiac Society)·2025
Same author

Never Give Up: Deep Hypothermic Circulatory Arrest for Transcatheter Mitral Edge-To-Edge Repair Failure in Porcelain Aorta - A Case Report.

Brazilian journal of cardiovascular surgery·2025
Same journal

Giornale italiano di cardiologia (2006)·2026
Same journal

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Bempedoic acid in real-world clinical practice: baseline and 8-week data from the Italian prospective, non-interventional MILOS study].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Ranolazine: established indications and emerging therapeutic potential].

Giornale italiano di cardiologia (2006)·2026
Same journal

[Kawasaki disease: the update of American Heart Association guidelines. What adult cardiologists need to know].

Giornale italiano di cardiologia (2006)·2026
Same journal

[The application of artificial intelligence in arrhythmology].

Giornale italiano di cardiologia (2006)·2026
See all related articles

Related Experiment Video

Updated: Nov 9, 2025

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

175

[Bempedoic acid: clinical data].

Pompilio Faggiano1, Nicola Bernardi2

  • 1Fondazione Poliambulanza, Brescia.

Giornale Italiano Di Cardiologia (2006)
|April 13, 2021
PubMed
Summary
This summary is machine-generated.

Bempedoic acid significantly reduces low-density lipoprotein cholesterol in patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia, demonstrating a favorable safety profile. Further studies are evaluating its long-term impact on cardiovascular events.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.7K

Related Experiment Videos

Last Updated: Nov 9, 2025

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

175
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH) are associated with elevated low-density lipoprotein cholesterol (LDL-C).
  • Statins are a first-line treatment but may not be sufficient or tolerated by all patients.
  • Novel lipid-lowering therapies are needed to manage hyperlipidemia and reduce cardiovascular risk.

Purpose of the Study:

  • To evaluate the efficacy and safety of bempedoic acid in patients with hyperlipidemia.
  • To assess the impact of bempedoic acid on LDL-C levels, particularly in patients on maximally tolerated statin therapy.
  • To investigate the occurrence of muscle-related adverse events associated with bempedoic acid.

Main Methods:

  • Phase 2 and phase 3 clinical trials were conducted to assess bempedoic acid.
  • Patients included those with ASCVD and/or FH, treated with statins at maximum tolerated dose.
  • Bempedoic acid treatment was compared against placebo or used as add-on therapy.

Main Results:

  • Phase 3 trials showed bempedoic acid significantly reduced LDL-C in various patient groups.
  • A favorable safety profile was observed, including in relation to muscle-related adverse events.
  • Ongoing phase 3 studies are assessing long-term cardiovascular event incidence with bempedoic acid.

Conclusions:

  • Bempedoic acid is an effective treatment for lowering LDL-C in patients with ASCVD and/or FH, including those on statins.
  • The drug exhibits a favorable safety profile, making it a viable option for lipid management.
  • Longer-term data from ongoing trials will further elucidate its role in cardiovascular event reduction.